

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Atanasio, Charles Confirmation No.: 3205
 Serial No.: 17/459,998 Group No.:
 Filing or 371(c) Date: July 27, 2021 Examiner:
 Entitled: Telehealth and Microdosing Platform for Psychedelic-Assisted Therapy

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application:

1. U.S. Pat. App. Pub. No. US/2020/0203025 “Connectivity Infrastructure for a Telehealth Platform with Third-Party Web Services” (Published June 25, 2020)
2. Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)
3. U.S. Pat. App. Pub. No. US/2022/0238222 “Remote Health Monitoring System and Method for Hospitals and Cities” (Published July 28, 2022)
4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)
5. Int’l. Pat. App. Pub. No. WO/2022/232933 “Personalized Microdosing Kits and Protocols Based on Biometric and Movement Data Correlated with Natural Product Qualities” (Published November 10, 2022)
6. Int’l. Pat. App. Pub. No. WO/2023/036473 “Combination Drug Therapies” (Published March 16, 2023)
7. Erowid Experience Vaults, “Psilocybin and Psilocin Dosage” July 11, 2006.
https://erowid.org/chemicals/psilocybin/psilocybin_dose.shtml

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 17/459,998 Pending Claims	References
<p>1. A method comprising: providing, on a first device associated with a patient user, a questionnaire comprising questions inquiring about well-being of the patient user; receiving, from the first device, responses of the patient user to the questionnaire;</p>	<p>1. U.S. Pat. App. Pub. No. US/2020/0203025 “Connectivity Infrastructure for a Telehealth Platform with Third-Party Web Services” (Published June 25, 2020)</p> <p>From Claim 1 “A telehealth system, comprising: a public communications network (PCN); a first server coupled to the PCN, the first server having a first address on the PCN; a second server coupled to the PCN, the second server having a second address on the PCN; a user device coupled to the PCN via a firewall that is configured to allow communications between the first address and the user”</p>

generating a patient user profile by applying machine learning to the responses, wherein the patient user profile comprises diagnostic questions customized for the patient user; providing, on a second device associated with a third party user, the patient user profile; initiating, via the first device and the second device, a video teleconference between the patient user and the third party user, wherein the third party user asks the patient user the diagnostic questions during the video teleconference to assess and diagnose a mental health of the patient user; and providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis, wherein the therapeutic treatment plan is indicative of at least one dosing session for the patient user to complete, frequency of the at least one dosing session, and an amount of psychedelics for the patient user to consume during the at least one dosing session.

device and block communications between the second address and the user device, wherein, when the first server receives a request from the user device that includes a request for a service provided by the second server, the first server relays the request from the user device to the second server and relays a response to the request from the second server to the user device.”

From **Claim 3** “The system of claim 2, wherein the service is a **videoconferencing service**”

3. U.S. Pat. App. Pub. No. US/2022/0238222 “Remote Health Monitoring System and Method for Hospitals and Cities” (Published July 28, 2022)

From **Claim 20** “The **telehealth system** according to claim 17, wherein the health-related user's data further comprise: an electronic medical record of the user and/or the **user's answers to the questions of a questionnaire**, the questionnaire comprising questions that are neutral to the user and questions that are generated by means of an algorithm based on the health-related user's data; and wherein the determination of at least one risk index is further based on the user's data in the electronic medical record and/or the user's answers to the questions of the questionnaire.”

4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)

From **Abstract** “The overall intelligence model may include multiple pieces. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, **inputs from healthcare and pharmaceutical experts, inputs the user provides based on questions the platform asks**, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system.”

From **Abstract** “As illustrated in Fig. 1, computing architecture 100 includes host system 110 that includes computing processing device 120 and data store 130. The host system 110, third-party system 140, and client device 150 are coupled to each other (e.g., may be operatively coupled, communicatively coupled, **may communicate data/messages with each other**) via network 105. Network 105 may be a public network (e.g., the internet), a private network (e.g., a local area network (LAN) or wide area network (WAN)), or a combination thereof. In one embodiment, network 105 may include a wired or a wireless infrastructure, which may be provided by one or more wireless communications systems, such as a WiFi' hotspot connected with the network 105 and/or a wireless carrier system that can be implemented using various data

	<p>processing equipment, communication towers (e.g. cell towers), etc. The network 105 may carry communications (e.g., data, message, packets, frames, etc.) between the various components of host system 110.”</p>
<p>2. The method of claim 1, wherein the third party user is a licensed therapist.</p>	<p>2. Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)</p> <p>From [0044] “Accordingly, systems and methods, such as those described herein, that provide, to a healthcare provider, one or more recommendations using, at least, treatment data pertaining to a user who uses the treatment device to perform a treatment plan, may be desirable.”</p> <p>5. Int’l. Pat. App. Pub. No. WO/2022/232933 “Personalized Microdosing Kits and Protocols Based on Biometric and Movement Data Correlated with Natural Product Qualities” (Published November 10, 2022)</p> <p>From [371] “In embodiments, individuals may additionally utilize the technology of the invention to consult, meet with, receive advice from, and/or merely have communication with, one or more “microdosing coaches.” In embodiments, such coaches may be licensed coaches, may be other users of the technology of the invention, and/or may be licensed therapists.”</p>
<p>3. The method of claim 1, wherein each dosing session is one of a microdosing session or a high dose session.</p>	<p>6. Int’l. Pat. App. Pub. No. WO/2023/036473 “Combination Drug Therapies” (Published March 16, 2023)</p> <p>From Abstract “This technology enables a healthcare provider to perform telehealth sessions with a patient, during which the healthcare provider can remotely activate and administer the 5-HT1A receptor agonist, the NMDA receptor antagonist, or both, via the desired delivery device while supervising the patient on the televisit.”</p> <p>From claim 40 “The method of claim 32, wherein the 5-HT2A receptor agonist is administered at a dose of about 0.01 mg/kg to about 3 mg/kg.”</p> <p>7. Erowid Experience Vaults, “Psilocybin and Psilocin Dosage” July 11, 2006. https://erowid.org/chemicals/psilocybin/psilocybin_dose.shtml</p>

Oral Psilocybin Dosages

Threshold	3 - 4 mg
Light	4 - 8 mg
Common	6 - 20 mg
Strong	20 - 40 mg
Heavy	35 + mg

4. The method of claim 1, further comprising: requesting feedback from the patient user, wherein the feedback is indicative of an experience and effects of the patient user after a dosing session.

2. Int'l. Pat. App. Pub. No. WO/2022/155251 "Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session" (Published July 21, 2022)

From **[0104]** "The system 10 also includes a patient interface 50 configured to **communicate information to a patient and to receive feedback from the patient.**"

4. U.S. Pat. App. Pub. No. US/2022/0238228 "Intelligent Telehealth Platform" (Published July 28, 2022)

From **Abstract** "As the user uses the products (e.g., during treatment) and follows the careplan that was produced by the IT platform 200, the feedback collector 216 may collect a series of inputs (sometimes referred to as, "feedback inputs" or "**feedback data**") **from the user.** In some embodiments, the feedback collector 216 may collect the series of feedback inputs from the user by sending data (e.g., instructions, code, data, questions, etc.) to the telehealth application 160 of the client device 150 to cause the telehealth application 160 to present a series of questions to the user on a display and send the user's responses to each of the questions to the feedback collector 216."

5. The method of claim 4, further comprising: requesting updated responses of the patient user to the questionnaire at pre-determined intervals after a first dosing session.

4. U.S. Pat. App. Pub. No. US/2022/0238222 "Remote Health Monitoring System and Method for Hospitals and Cities" (Published July 28, 2022)

From **Claim 20** "The telehealth system according to claim 17, wherein the health-related user's data further comprise: an electronic medical record of the user and/or **the user's answers to the questions of a questionnaire,** the questionnaire comprising questions that are neutral to the user and questions that are generated by means of an algorithm based on the health-related user's data; and wherein the determination of at least one risk index is further based on the user's data in the electronic medical record and/or the user's answers to the questions of the questionnaire."

4. U.S. Pat. App. Pub. No. US/2022/0238228 "Intelligent Telehealth Platform" (Published July 28, 2022)

	<p>From Abstract “As discussed below, the regimen recommendation model 209 updates its recommendation when new feedback inputs are provided. The inputs for the feedback are processed in the feedback processing model 220. The new recommendation is used to generate an updated careplan draft for the next phase of the process. In some embodiments, the feedback processing model 220 may also ingest one or more of the inputs (as discussed herein) that are ingested by the user profile collector 202.”</p>
<p>6. The method of claim 5, further comprising: monitoring satisfaction of the patient user with the therapeutic treatment plan based on at least one of the feedback or the updated responses.</p>	<p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p> <p>From Abstract “The overall intelligence model may include multiple pieces. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, inputs from healthcare and pharmaceutical experts, inputs the user provides based on questions the platform asks, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system.”</p> <p>From Abstract “The patient success node may be based on how well that type of user does with the output from the model recommended. The outputs from the feedback processing model 220 for patient satisfaction may be used as inputs for this model to provide evidence for the patient success node.”</p> <p>From Abstract “The feedback processing model 220 computes overall progress and satisfaction, as well as the most likely adjustments needed to the careplan”</p>
<p>7. The method of claim 6, further comprising: requesting the third party user to make an adjustment to the therapeutic treatment plan based on at least one of the feedback, the updated responses, or the satisfaction of the patient user with the therapeutic treatment plan.</p>	<p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p> <p>From Abstract “The feedback processing model 220 computes overall progress and satisfaction, as well as the most likely adjustments needed to the careplan”</p> <p>From Abstract “In some embodiments, the IT platform 200 may be configured to further train (e.g., tune) the regimen recommendation model 208 by matching physician recommendations to the model output. The IT platform 200 may continually re-train (e.g., update) the recommendation model 209 using the dataset generated from one or more of the users of the intelligent telehealth platform 200, their user profile data, all their feedback inputs, the careplan attributes for recommended products by phase, and/or their progress in well-being and activity improvement metrics. In some embodiments, the IT platform 200 may estimate the one or more probabilities in each node of the recommendation model 209 based on trial results and physician knowledge and experiences to represent the uncertainty throughout the model.”</p>

<p>8. A system, comprising: at least one processor; and a non-transitory processor-readable memory device storing instructions that when executed by the at least one processor causes the at least one processor to perform operations including: providing, on a first device associated with a patient user, a questionnaire comprising questions inquiring about well-being of the patient user; receiving, from the first device, responses of the patient user to the questionnaire; generating a patient user profile by applying machine learning to the responses, wherein the patient user profile comprises diagnostic questions customized for the patient user; providing, on a second device associated with a third party user, the patient user profile; initiating, via the first device and the second device, a video teleconference between the patient user and the third party user, wherein the third party user asks the patient user the diagnostic questions during the video teleconference to assess and diagnose a mental health of the patient user; and providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis, wherein the therapeutic treatment plan is indicative of at least one dosing session for the patient user to complete, frequency of the at least one dosing session, and an amount of psychedelics for the patient user to</p>	<p>1. U.S. Pat. App. Pub. No. US/2020/0203025 “Connectivity Infrastructure for a Telehealth Platform with Third-Party Web Services” (Published June 25, 2020)</p> <p>From Claim 1 “A telehealth system, comprising: a public communications network (PCN); a first server coupled to the PCN, the first server having a first address on the PCN; a second server coupled to the PCN, the second server having a second address on the PCN; a user device coupled to the PCN via a firewall that is configured to allow communications between the first address and the user device and block communications between the second address and the user device, wherein, when the first server receives a request from the user device that includes a request for a service provided by the second server, the first server relays the request from the user device to the second server and relays a response to the request from the second server to the user device.”</p> <p>From Claim 3 “The system of claim 2, wherein the service is a videoconferencing service”</p> <p>3. U.S. Pat. App. Pub. No. US/2022/0238222 “Remote Health Monitoring System and Method for Hospitals and Cities” (Published July 28, 2022)</p> <p>From Claim 20 “The telehealth system according to claim 17, wherein the health-related user's data further comprise: an electronic medical record of the user and/or the user's answers to the questions of a questionnaire, the questionnaire comprising questions that are neutral to the user and questions that are generated by means of an algorithm based on the health-related user's data; and wherein the determination of at least one risk index is further based on the user's data in the electronic medical record and/or the user's answers to the questions of the questionnaire.”</p> <p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p> <p>From Abstract “The overall intelligence model may include multiple pieces. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, inputs from healthcare and pharmaceutical experts, inputs the user provides based on questions the platform asks, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system.”</p>
---	--

<p>consume during the at least one dosing session.</p>	<p>From Abstract “As illustrated in FIG. 1, computing architecture 100 includes host system 110 that includes computing processing device 120 and data store 130. The host system 110, third-party system 140, and client device 150 are coupled to each other (e.g., may be operatively coupled, communicatively coupled, may communicate data/messages with each other) via network 105. Network 105 may be a public network (e.g., the internet), a private network (e.g., a local area network (LAN) or wide area network (WAN)), or a combination thereof. In one embodiment, network 105 may include a wired or a wireless infrastructure, which may be provided by one or more wireless communications systems, such as a WiFi’ hotspot connected with the network 105 and/or a wireless carrier system that can be implemented using various data processing equipment, communication towers (e.g. cell towers), etc. The network 105 may carry communications (e.g., data, message, packets, frames, etc.) between the various components of host system 110.”</p>
<p>9. The system of claim 8, wherein the third party user is a licensed therapist.</p>	<p>2. Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)</p> <p>From [0044] “Accordingly, systems and methods, such as those described herein, that provide, to a healthcare provider, one or more recommendations using, at least, treatment data pertaining to a user who uses the treatment device to perform a treatment plan, may be desirable.”</p> <p>5. Int’l. Pat. App. Pub. No. WO/2022/232933 “Personalized Microdosing Kits and Protocols Based on Biometric and Movement Data Correlated with Natural Product Qualities” (Published November 10, 2022)</p> <p>From [371] “In embodiments, individuals may additionally utilize the technology of the invention to consult, meet with, receive advice from, and/or merely have communication with, one or more “microdosing coaches.” In embodiments, such coaches may be licensed coaches, may be other users of the technology of the invention, and/or may be licensed therapists.”</p>
<p>10. The system of claim 8, wherein each dosing session is one of a microdosing session or a high dose session.</p>	<p>6. Int’l. Pat. App. Pub. No. WO/2023/036473 “Combination Drug Therapies” (Published March 16, 2023)</p> <p>From Abstract “This technology enables a healthcare provider to perform telehealth sessions with a patient, during which the healthcare provider can remotely activate and administer the 5-HT1A receptor agonist, the NMDA receptor antagonist, or both, via the desired delivery device while supervising the patient on the televisit.”</p>

	<p>From Claim 40 “The method of claim 32, wherein the 5-HT2A receptor agonist is administered at a dose of about 0.01 mg/kg to about 3 mg/kg.”</p> <p>7. Erowid Experience Vaults, “Psilocybin and Psilocin Dosage” July 11, 2006. https://erowid.org/chemicals/psilocybin/psilocybin_dose.shtml</p> <div data-bbox="834 621 1177 982" style="border: 2px solid black; padding: 5px; margin: 10px auto; width: fit-content;"> <table border="1" style="border-collapse: collapse; width: 100%; text-align: center;"> <thead> <tr> <th colspan="2" style="background-color: #f0f0f0;">Oral Psilocybin Dosages</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px 5px;">Threshold</td> <td style="padding: 2px 5px;">3 - 4 mg</td> </tr> <tr> <td style="padding: 2px 5px;">Light</td> <td style="padding: 2px 5px;">4 - 8 mg</td> </tr> <tr> <td style="padding: 2px 5px;">Common</td> <td style="padding: 2px 5px;">6 - 20 mg</td> </tr> <tr> <td style="padding: 2px 5px;">Strong</td> <td style="padding: 2px 5px;">20 - 40 mg</td> </tr> <tr> <td style="padding: 2px 5px;">Heavy</td> <td style="padding: 2px 5px;">35 + mg</td> </tr> </tbody> </table> </div>	Oral Psilocybin Dosages		Threshold	3 - 4 mg	Light	4 - 8 mg	Common	6 - 20 mg	Strong	20 - 40 mg	Heavy	35 + mg
Oral Psilocybin Dosages													
Threshold	3 - 4 mg												
Light	4 - 8 mg												
Common	6 - 20 mg												
Strong	20 - 40 mg												
Heavy	35 + mg												
<p>11. The system of claim 8, wherein the operations include: requesting feedback from the patient user, wherein the feedback is indicative of an experience and effects of the patient user after a dosing session.</p>	<p>2. Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)</p> <p>From [0104] “The system 10 also includes a patient interface 50 configured to communicate information to a patient and to receive feedback from the patient.”</p> <p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p> <p>From Abstract “As the user uses the products (e.g., during treatment) and follows the careplan that was produced by the IT platform 200, the feedback collector 216 may collect a series of inputs (sometimes referred to as, “feedback inputs” or “feedback data”) from the user. In some embodiments, the feedback collector 216 may collect the series of feedback inputs from the user by sending data (e.g., instructions, code, data, questions, etc.) to the telehealth application 160 of the client device 150 to cause the telehealth application 160 to present a series of questions to the user on a display and send the user's responses to each of the questions to the feedback collector 216.”</p>												
<p>12. The system of claim 11, wherein the operations include:</p>	<p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p>												

<p>requesting updated responses of the patient user to the questionnaire at pre-determined intervals after a first dosing session.</p>	<p>From Abstract “The overall intelligence model may include multiple pieces. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, inputs from healthcare and pharmaceutical experts, inputs the user provides based on questions the platform asks, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system.”</p>
<p>13. The system of claim 12, wherein the operations include: monitoring satisfaction of the patient user with the therapeutic treatment plan based on at least one of the feedback or the updated responses.</p>	<p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p> <p>From Abstract “The patient success node may be based on how well that type of user does with the output from the model recommended. The outputs from the feedback processing model 220 for patient satisfaction may be used as inputs for this model to provide evidence for the patient success node.”</p> <p>From Abstract “The feedback processing model 220 computes overall progress and satisfaction, as well as the most likely adjustments needed to the careplan”</p>
<p>14. The system of claim 13, wherein the operations include: requesting the third party user to make an adjustment to the therapeutic treatment plan based on at least one of the feedback, the updated responses, or the satisfaction of the patient user with the therapeutic treatment plan.</p>	<p>2. Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)</p> <p>From [0104] “The system 10 also includes a patient interface 50 configured to communicate information to a patient and to receive feedback from the patient.”</p> <p>4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)</p> <p>From Abstract “As the user uses the products (e.g., during treatment) and follows the careplan that was produced by the IT platform 200, the feedback collector 216 may collect a series of inputs (sometimes referred to as, “feedback inputs” or “feedback data”) from the user. In some embodiments, the feedback collector 216 may collect the series of feedback inputs from the user by sending data (e.g., instructions, code, data, questions, etc.) to the telehealth application 160 of the client device 150 to cause the telehealth application 160 to present a series of questions to the user on a display and send the user's responses to each of the questions to the feedback collector 216.”</p>
<p>15. A non-transitory processor-readable medium that includes a program that when executed by a processor performs a method comprising: providing, on a first device associated with a patient user,</p>	<p>1. U.S. Pat. App. Pub. No. US/2020/0203025 “Connectivity Infrastructure for a Telehealth Platform with Third-Party Web Services” (Published June 25, 2020)</p> <p>From Claim 1 “A telehealth system, comprising: a public communications network (PCN);</p>

a questionnaire comprising questions inquiring about well-being of the patient user; receiving, from the first device, responses of the patient user to the questionnaire; generating a patient user profile by applying machine learning to the responses, wherein the patient user profile comprises diagnostic questions customized for the patient user; providing, on a second device associated with a third party user, the patient user profile; initiating, via the first device and the second device, a video teleconference between the patient user and the third party user, wherein the third party user asks the patient user the diagnostic questions during the video teleconference to assess and diagnose a mental health of the patient user; and providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis, wherein the therapeutic treatment plan is indicative of at least one dosing session for the patient user to complete, frequency of the at least one dosing session, and an amount of psychedelics for the patient user to consume during the at least one dosing session.

a **first server** coupled to the PCN, the first server having a first address on the PCN;
a **second server** coupled to the PCN, the second server having a second address on the PCN;
a **user device** coupled to the PCN via a firewall that is configured to allow communications between the first address and the user device and block communications between the second address and the user device,
wherein, when the first server receives a request from the user device that includes a request for a service provided by the second server, the first server relays the request from the user device to the second server and relays a response to the request from the second server to the user device.”

From **Claim 3** “The system of claim 2, wherein the service is a **videoconferencing** service”

3. U.S. Pat. App. Pub. No. US/2022/0238222 “Remote Health Monitoring System and Method for Hospitals and Cities” (Published July 28, 2022)

From **Claim 20** “The **telehealth system** according to claim 17, wherein the health-related user's data further comprise: an electronic medical record of the user and/or **the user's answers to the questions of a questionnaire**, the questionnaire comprising questions that are neutral to the user and questions that are generated by means of an algorithm based on the health-related user's data; and wherein the determination of at least one risk index is further based on the user's data in the electronic medical record and/or the user's answers to the questions of the questionnaire.”

4. U.S. Pat. App. Pub. No. US/2022/0238228 “Intelligent Telehealth Platform” (Published July 28, 2022)


From **Abstract** “The overall intelligence model may include **multiple pieces**. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, **inputs from healthcare and pharmaceutical experts**, **inputs the user provides based on questions the platform asks**, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system.”

From **Abstract** “As illustrated in FIG. 1, computing architecture 100 includes **host system** 110 that includes computing processing device 120 and **data store** 130. The host system 110, third-party system 140, and client device 150 are coupled to each other (e.g., may be operatively coupled, communicatively coupled, may communicate data/messages with each other) via network 105. Network 105 may be a public network (e.g., the internet), a private

	<p>network (e.g., a local area network (LAN) or wide area network (WAN)), or a combination thereof. In one embodiment, network 105 may include a wired or a wireless infrastructure, which may be provided by one or more wireless communications systems, such as a WiFi hotspot connected with the network 105 and/or a wireless carrier system that can be implemented using various data processing equipment, communication towers (e.g. cell towers), etc. The network 105 may carry communications (e.g., data, message, packets, frames, etc.) between the various components of host system 110.”</p>
<p>16. The non-transitory processor-readable medium of claim 15, wherein the third party user is a licensed therapist.</p>	<p>2. Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)</p> <p>From [0044] “Accordingly, systems and methods, such as those described herein, that provide, to a healthcare provider, one or more recommendations using, at least, treatment data pertaining to a user who uses the treatment device to perform a treatment plan, may be desirable.”</p> <p>5. Int’l. Pat. App. Pub. No. WO/2022/232933 “Personalized Microdosing Kits and Protocols Based on Biometric and Movement Data Correlated with Natural Product Qualities” (Published November 10, 2022)</p> <p>From [371] “In embodiments, individuals may additionally utilize the technology of the invention to consult, meet with, receive advice from, and/or merely have communication with, one or more “microdosing coaches.” In embodiments, such coaches may be licensed coaches, may be other users of the technology of the invention, and/or may be licensed therapists.”</p>
<p>17. The non-transitory processor-readable medium of claim 15, wherein each dosing session is one of a microdosing session or a high dose session.</p>	<p>6. Int’l. Pat. App. Pub. No. WO/2023/036473 “Combination Drug Therapies” (Published March 16, 2023)</p> <p>From Abstract “This technology enables a healthcare provider to perform telehealth sessions with a patient, during which the healthcare provider can remotely activate and administer the 5-HT1A receptor agonist, the NMDA receptor antagonist, or both, via the desired delivery device while supervising the patient on the televisit.”</p> <p>From Claim 40 “The method of claim 32, wherein the 5-HT2A receptor agonist is administered at a dose of about 0.01 mg/kg to about 3 mg/kg.”</p> <p>7. Erowid Experience Vaults, “Psilocybin and Psilocin Dosage” July 11, 2006. https://erowid.org/chemicals/psilocybin/psilocybin_dose.shtml</p>

Oral Psilocybin Dosages

Threshold	3 - 4 mg
Light	4 - 8 mg
Common	6 - 20 mg
Strong	20 - 40 mg
Heavy	35 + mg

	<p style="text-align: center;">  </p>
<p>18. The non-transitory processor-readable medium of claim 15, wherein the method further comprises: requesting feedback from the patient user, wherein the feedback is indicative of an experience and effects of the patient user after a dosing session.</p>	<p>2. Int'l. Pat. App. Pub. No. WO/2022/155251 "Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session" (Published July 21, 2022)</p> <p>From [0104] "The system 10 also includes a patient interface 50 configured to communicate information to a patient and to receive feedback from the patient."</p> <p>4. U.S. Pat. App. Pub. No. US/2022/0238228 "Intelligent Telehealth Platform" (Published July 28, 2022)</p> <p>From Abstract "As the user uses the products (e.g., during treatment) and follows the careplan that was produced by the IT platform 200, the feedback collector 216 may collect a series of inputs (sometimes referred to as, "feedback inputs" or "feedback data") from the user. In some embodiments, the feedback collector 216 may collect the series of feedback inputs from the user by sending data (e.g., instructions, code, data, questions, etc.) to the telehealth application 160 of the client device 150 to cause the telehealth application 160 to present a series of questions to the user on a display and send the user's responses to each of the questions to the feedback collector 216."</p>
<p>19. The non-transitory processor-readable medium of claim 18, wherein the method further comprises: requesting updated responses of the patient user to the questionnaire at pre-determined intervals after a first dosing session.</p>	<p>4. U.S. Pat. App. Pub. No. US/2022/0238228 "Intelligent Telehealth Platform" (Published July 28, 2022)</p> <p>From Abstract "The overall intelligence model may include multiple pieces. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, inputs from healthcare and pharmaceutical experts, inputs the user provides based on questions the platform asks, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system."</p>
<p>20. The non-transitory processor-readable medium of claim 19, wherein the method further comprises:</p>	<p>4. U.S. Pat. App. Pub. No. US/2022/0238228 "Intelligent Telehealth Platform" (Published July 28, 2022)</p>

<p>monitoring satisfaction of the patient user with the therapeutic treatment plan based on at least one of the feedback or the updated responses; requesting the third party user to make an adjustment to the therapeutic treatment plan based on at least one of the feedback, the updated responses, or the satisfaction of the patient user with the therapeutic treatment plan; and uploading and storing in one or more electronic medical records of the patient user the feedback, the updated responses, one or more certifications of the third party user, and at least one record of at least one session between the patient user and the third party user.</p>	<p>From Abstract “The overall intelligence model may include multiple pieces. At a high level are the inputs of the data used by the model. Such data may include user profiling inputs, product inventory, inputs from healthcare and pharmaceutical experts, inputs the user provides based on questions the platform asks, data indicative of physician expertise and experience associated with cannabis, physician approval of the recommended treatment plan, and/or data on how the user interacts with the system.”</p> <p>From Abstract “The patient success node may be based on how well that type of user does with the output from the model recommended. The outputs from the feedback processing model 220 for patient satisfaction may be used as inputs for this model to provide evidence for the patient success node.”</p> <p>From Abstract “The feedback processing model 220 computes overall progress and satisfaction, as well as the most likely adjustments needed to the careplan”</p> <p>From Abstract “As the user uses the products (e.g., during treatment) and follows the careplan that was produced by the IT platform 200, the feedback collector 216 may collect a series of inputs (sometimes referred to as, “feedback inputs” or “feedback data”) from the user. In some embodiments, the feedback collector 216 may collect the series of feedback inputs from the user by sending data (e.g., instructions, code, data, questions, etc.) to the telehealth application 160 of the client device 150 to cause the telehealth application 160 to present a series of questions to the user on a display and send the user's responses to each of the questions to the feedback collector 216.”</p> <p>2 Int’l. Pat. App. Pub. No. WO/2022/155251 “Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in real-time during a telemedicine session” (Published July 21, 2022)</p> <p>From [0104] “The system 10 also includes a patient interface 50 configured to communicate information to a patient and to receive feedback from the patient.”</p>
--	---

Electronic Acknowledgement Receipt

EFS ID:	48139606
Application Number:	17459998
International Application Number:	
Confirmation Number:	3205
Title of Invention:	TELEHEALTH AND MICRODOSING PLATFORM FOR PSYCHEDELIC-ASSISTED THERAPY
First Named Inventor/Applicant Name:	Charles John Atanasio
Customer Number:	99435
Filer:	Taylor Kurtzweil
Filer Authorized By:	
Attorney Docket Number:	ATA1-P.e01
Receipt Date:	12-JUN-2023
Filing Date:	27-AUG-2021
Time Stamp:	18:15:42
Application Type:	

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Concise Description of Relevance	Concise-description-generated.pdf	38835 bac13f2550ce1c1ccd1515088622e4c5d2351311	no	4

Warnings:

Information:					
2	Third-Party Submission Under 37 CFR 1.290	Third-party-preissuance-submission.pdf	65136 551c704209eac6810d1c5d5942b93da468db5937	no	3
Warnings:					
Information:					
3	Request for Notification of Non-compliant Third-Party Submission	Third-party-notification-request.pdf	23740 955316f769754c541e994e3887410b56e0d50b50	no	1
Warnings:					
Information:					
4	Evidence of Publication	WO2022155251.pdf	5136781 c43cc5176426ce0f48de4a055c4924c9509d9216	no	105
Warnings:					
Information:					
5	Evidence of Publication	WO2022232933.pdf	7962038 a87b3c7842d4aba38a00465e4a6479aea02ae723	no	142
Warnings:					
Information:					
6	Concise Description of Relevance	20230065820_Claims_Chart.pdf	230758 42468426bc2a83b6e4f5d54fd100c1ca46b29789	no	13
Warnings:					
Information:					
7	Evidence of Publication	Erowid.pdf	519931 f49bd06a9a78b09355dd53a2fb5953def7df6d6c	no	1
Warnings:					
Information:					
8	Evidence of Publication	WO2023036473Compressed.pdf	4311327 78b25b37d3b6860e3124557c9b24c90129040ddb	no	216
Warnings:					
Information:					
Total Files Size (in bytes):				18288546	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.